

**Title:** Long Term Outcomes of Trabeculectomy Augmented with Mitomycin-C Undertaken within the First Two Years of Life

**Running Head:** MMC Trabeculectomy within the First Two Years of Life

**Authors:** Hari Jayaram PhD FRCSEd<sup>1,2,3</sup>, Richard Scawn FRCOphth<sup>1</sup>, Francisco Pooley MD<sup>1,4</sup>, Mark Chiang MB BS FRANZCO<sup>1,2,5</sup>, Catey Bunce BSc (Hons), MSc, DSc<sup>2,6</sup>, Nicholas G Strouthidis PhD FRCOphth<sup>1,2,7,8</sup>, Peng Tee Khaw PhD FRCOphth<sup>1,2</sup>, Maria Papadopoulos MB BS FRANZCO FRCOphth<sup>1,2</sup>

**Institutions:** <sup>1</sup>Glaucoma Service, Moorfields Eye Hospital, London, United Kingdom  
<sup>2</sup>NIHR Biomedical Research Centre for Ophthalmology, UCL Institute of Ophthalmology & Moorfields Eye Hospital, London, United Kingdom  
<sup>3</sup>Casey Eye Institute, Portland, OR, USA  
<sup>4</sup>Glaucoma Department, Fundación Oftalmológica Los Andes, Santiago, Chile  
<sup>5</sup>Queensland Eye Institute & City Eye Centre, Brisbane, Australia  
<sup>6</sup>London School of Hygiene & Tropical Medicine  
<sup>7</sup>Singapore Eye Research Institute, Singapore  
<sup>8</sup>Discipline of Clinical Ophthalmology and Eye Health, University of Sydney, Australia

**Address for Reprints:**

Miss Maria Papadopoulos  
Consultant Ophthalmic Surgeon  
Glaucoma Service  
Moorfields Eye Hospital  
162 City Road  
London EC1V 2PD  
United Kingdom.  
Phone: +44 (20) 7566 2989  
Fax: +44 (20) 7566 2334  
Email: [maria.papadopoulos@moorfields.nhs.uk](mailto:maria.papadopoulos@moorfields.nhs.uk)

**Conflict of Interest**

No conflicting relationship exists for any author and all have no proprietary or commercial interest in any materials discussed.

**Financial Disclosure(s)**

HJ, CB, NGS, PTK and MP acknowledge a proportion of their financial support from the UK Department of Health through the award made by the National Institute for Health Research to Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology for a Biomedical Research Centre for Ophthalmology. Our work with Childhood Glaucoma is also supported in part by the Moorfields Special Trustees, Moorfields Eye Charity, Lady Helen Hamlyn, Michael and Ilsa Katz, Ron and Liora Moskovitz. HJ is currently supported by a fellowship awarded by the Fulbright Commission in association with Fight for Sight. The views expressed in this publication are those of the authors and not necessarily those of the UK Department of Health.

## **Précis**

Contemporary pediatric trabeculectomy technique with mitomycin-C in phakic infants with glaucoma can be associated with long term IOP control off medications and with satisfactory visual outcomes.

## Abstract

**Purpose:** To evaluate the long-term effectiveness and safety of mitomycin-C (MMC) augmented trabeculectomy undertaken within the first two years of life for the surgical management of glaucoma.

**Design:** Retrospective, consecutive, non-comparative case series.

**Participants:** All children who underwent MMC augmented trabeculectomy within two years of birth between May 2002 and November 2012.

**Methods:** The medical records of 40 consecutive eyes of 26 children who underwent surgery by a single surgeon were reviewed. Data collected during routine clinical care were analyzed.

**Main Outcome Measures:** Assessment of clinical outcomes included intraocular pressure (IOP), final visual acuity, bleb morphology, surgical complications (early and late), postoperative interventions and further glaucoma surgery performed. Surgical success was defined as  $5\text{mmHg} \leq \text{final IOP} \leq 21\text{mmHg}$ , with anti-glaucoma medications (qualified success) and without (complete success), stable ocular dimensions and optic disc cupping, no further glaucoma surgery (including needling) or loss of light perception. Surgical outcomes were evaluated using Kaplan-Meier life-table analysis.

**Results:** 40 eyes of 26 children were studied over a mean follow up period of 62.8 months. The majority of cases (80%) were primary congenital glaucomas following failed goniotomy surgery. Cumulative probabilities of survival at 1, 5 & 7 years were 78%, 67% and 60% respectively. Of eyes regarded as successful, 96% (25/26 eyes) had controlled IOP off topical medication, and 44% achieved visual acuity of 20/40 or better. Only one of the 40 eyes developed a cystic avascular bleb with all the other eyes being non-cystic in nature (diffuse and elevated or flat) at final follow up. Sixty-four percent (9/14 eyes) of cases regarded as failures ultimately underwent glaucoma drainage device implantation.

**Conclusions:** Contemporary pediatric trabeculectomy technique augmented with MMC is an effective procedure in the management of glaucoma within the first two years of life, as shown by the successful long-term outcomes and low incidence of sight threatening complications. Trabeculectomy, following failed goniotomy surgery, or as a primary surgical intervention may offer a phakic infant with glaucoma an excellent opportunity to achieve long-term control of intraocular pressure off medications and be associated with optimal visual outcomes.

# 1 Introduction

2 Childhood glaucoma is an uncommon disorder characterized by elevated intraocular  
3 pressure (IOP) related damage to the eye that can be caused by a diverse group of  
4 conditions. The ultimate therapeutic goal in children with glaucoma is to provide a lifetime of  
5 vision, for which successful control of IOP is crucial. Medical therapy plays an important role  
6 in controlling IOP but the mainstay of treatment is surgery, which usually needs to be  
7 repeated<sup>1-4</sup>. Surgical intervention is often the case for glaucoma presenting in infancy, that is  
8 within the first two years of life. The surgical procedure of choice is largely determined by the  
9 type of glaucoma and may be further influenced by factors such as corneal clarity and the  
10 surgeon's experience and practice. The outcomes and longevity of surgical interventions  
11 may have a significant impact upon the future quality of life of both children and their  
12 families<sup>5</sup>.

13

14 Primary congenital glaucoma (PCG) is the commonest glaucoma in infancy<sup>1, 4</sup> for which  
15 angle surgery (goniotomy or trabeculotomy) is widely regarded as the primary surgical  
16 intervention of choice<sup>6</sup> due to successful reported outcomes<sup>7-9</sup>. Poorer outcomes from angle  
17 surgery are usually reported for secondary childhood glaucomas<sup>10, 11</sup>. Traditionally,  
18 trabeculectomy was indicated following failed angle surgery. However, trabeculectomy  
19 surgery in children is especially challenging as it is less successful when compared to  
20 adults<sup>12, 13</sup> because of a vigorous healing response<sup>14</sup>. This has necessitated the use of  
21 adjunctive anti-scarring agents such as mitomycin-C (MMC) but at the cost of an increased  
22 risk of potentially serious complications such as hypotony and bleb related problems.<sup>15-19</sup>  
23 However even with MMC, the literature suggests disappointing outcomes for trabeculectomy  
24 in infants (especially less than one year of age) when compared to older children<sup>15, 16, 18, 20</sup>  
25 and also when compared to glaucoma drainage devices (GDD)<sup>21</sup>. GDD in children carry a  
26 significant risk of tube related problems such as tube-cornea touch in up to 26% cases<sup>21-23</sup>  
27 and tube migration or extrusion often necessitating the need for further tube related surgery

28 in up to a third of cases<sup>3, 21</sup>. Consequently, there is no consensus on the optimum surgery  
29 following failed angle surgery<sup>6</sup>.

30

31 Contemporary trabeculectomy techniques involving fornix-based conjunctival dissection,  
32 releasable sutures and a wide area of anti-scarring application (a technique often described  
33 as the Moorfields Safer Surgery System)<sup>24, 25</sup> have evolved over the past 15 years with the  
34 aim of encouraging posterior aqueous flow and the development of diffuse drainage blebs.  
35 These changes were developed to reduce the high incidence of sight threatening  
36 complications, particularly bleb related problems, in children and subsequently applied to  
37 adult surgery.<sup>26, 27</sup> The aim of this study was therefore to evaluate the long-term safety and  
38 effectiveness of this surgical technique in infants undergoing trabeculectomy within the first  
39 two years of life.

40

## 41 **Patients and Methods**

42 The protocol for this project was granted institutional review board approval by the Clinical  
43 Audit Assessment Committee of Moorfields Eye Hospital. A retrospective case note review  
44 was performed on the records of all children aged two years or younger that underwent  
45 MMC augmented trabeculectomy by a single surgeon (MP) between May 2002 and  
46 November 2012. Some children underwent sequential surgery to both eyes but no  
47 simultaneous bilateral surgery was performed. In these situations, each individual eye was  
48 regarded as a separate data entity for the purpose of analysis. All cases had a minimum of  
49 12 months of follow up.

50

### 51 **Standard Surgical Technique**

52 The surgical procedure involved the creation of a superior fornix-based conjunctival peritomy  
53 and a rectangular (5mm x 4mm) lamellar scleral flap with a crescent blade at the 12 o' clock  
54 position. Due to the very elastic nature of the infantile sclera, only short radial cuts were

55 made which enabled tight closure without the need to suture the radial edge of the flap whilst  
56 also encouraging posterior aqueous flow. A wide area of subconjunctival space  
57 (approximately 3 clock hours) was then treated with MMC soaked Merocel corneal shields  
58 (Beaver Visitec, UK), as was the undersurface of the scleral flap with a tear film strip (Sno-  
59 strips, Chauvin Pharmaceuticals Limited, UK) cut to size. MMC was applied at  
60 concentrations varying between 0.1-0.5mg/ml (at surgeon's discretion dependent upon risk  
61 factors for failure) for 3 minutes before irrigation with 20ml of balanced salt solution. 10-0  
62 nylon (Alcon, UK) was used to preplace intralaminar scleral sutures, with a fixed suture at  
63 each corner and two releasable sutures at the posterior edge of the scleral flap. Following  
64 insertion of an anterior chamber (AC) maintainer (Lewicky, Beaver Visitec UK), the AC was  
65 entered at the anterior edge of the scleral bed. A 500µm sclerostomy was created with a  
66 Khaw Descemet membrane punch 7-101 (Duckworth & Kent, UK) followed by a surgical  
67 iridectomy. Further sutures were placed in the scleral flap, as required, with the aim of  
68 achieving no aqueous flow through the flap at the end of procedure. Tenonectomy was not  
69 performed. The conjunctiva was closed with 10-0 nylon sutures and in most cases a small  
70 volume of viscoelastic (usually Provisc® (Alcon, UK)) and sterile air were injected into the  
71 AC. Subconjunctival injections of steroid (Betamethasone) and antibiotic (Cefuroxime) were  
72 given at the end of the case. All eyes were patched overnight.

73

74 Postoperatively, all patients received daily intensive steroid drops (dexamethasone 0.1%)  
75 every 2-3 hours and ointment at night (Maxitrol – dexamethasone, neomycin sulfate and  
76 polymyxin b sulfate ointment). Topical steroids were gradually weaned over 3-5 months as  
77 dictated by the degree of conjunctival inflammation. Antibiotic drops (Chloramphenicol) four  
78 times a day were usually stopped within 2-3 weeks of surgery once all exposed sutures were  
79 removed. Cycloplegics were not routinely administered. Parents were advised to tape a  
80 plastic shield over the operated eye at night time for the first month after surgery.

81

82 **Postoperative Management**

83 All children were examined at 1 day, 1 week, three weeks and six weeks after surgery, with  
84 subsequent outpatient visits dependent upon clinical progress. Examination under Ketamine  
85 anesthesia (EUA) took place at 1, 3 and 6 weeks after surgery when releasable sutures  
86 were loosened or removed and subconjunctival steroid and/or 5-fluorouracil (5-FU) injections  
87 (0.2-0.3ml of 50mg/ml solution) administered depending upon the characteristics of the bleb  
88 and the degree of bleb inflammation. Measurements of corneal diameter and axial length  
89 were also performed. Subsequently, additional glaucoma surgery was undertaken in eyes  
90 uncontrolled by glaucoma medications.

91

92 Visual acuity, IOP, slit lamp biomicroscopy examining bleb morphology, anterior chamber  
93 depth, wound status and lens clarity were routinely performed along with evaluation of the  
94 optic nerve and retina at each postoperative visit. Quantitative visual acuity was measured  
95 when the child's age and developmental abilities allowed. IOP measurements were obtained  
96 using either Perkins applanation tonometry under Ketamine anesthesia, rebound tonometry  
97 (Icare, Finland) or Goldmann applanation tonometry as the children became older.

98 Amblyopia was appropriately treated with refractive correction and a patching regime.

99

## 100 **Outcome Measures**

101 Surgical success was defined as  $IOP \leq 21$ mmHg and  $\geq 5$ mmHg either with (qualified success)  
102 or without (complete success) topical glaucoma medications, no further glaucoma surgery  
103 (including bleb needling which was considered a failure), no devastating complications or the  
104 loss of light perception vision and stable ocular dimensions (axial length, corneal diameter)  
105 and optic disc cupping. Manipulation of the scleral flap (bleb massage), removal/adjustment  
106 of releasable sutures were not considered as criteria for failure, as these comprise routine  
107 post-surgical care with the technique employed. Complications and details of postoperative  
108 interventions following the initial trabeculectomy were noted.

109

## 110 **Statistical Methods**

111 Data analysis was performed using Graphpad Prism (Graphpad, USA). Demographic data  
112 were reported as the mean  $\pm$  standard error with the range specified. Surgical success was  
113 evaluated by Kaplan-Meier life-table analysis. Survival curves between subgroups were  
114 compared using the log-rank (Mantel-Cox) test with Chi-Squared significance test.  
115 Parameters between the groups designated success and failure were compared using either  
116 a two-tailed unpaired *t*-test with Welch's correction or else by a Mann-Whitney Test,  
117 depending on whether the populations fitted a Gaussian distribution as shown by the  
118 D'Agostino & Pearson normality test. Retrospective contingency table analysis was  
119 performed using a two-tailed Fishers Exact Test. Statistical significance was considered for  
120 values at  $p < 0.05$ .

121

## 122 **Results**

### 123 **Patient Demographics and Preoperative Clinical Status**

124 Forty consecutive eyes of twenty-six children were identified as having undergone MMC  
125 augmented trabeculectomy before two years of age within the designated study period. The  
126 full patient record was available for all the cases identified and the baseline demographic  
127 data of the group studied are summarized in Table 1. Children ranged in age from 1 to 19  
128 months with a mean of  $9.0 \pm 0.8$  months. All eyes were phakic and most had PCG that had  
129 undergone previous angle surgery in the form of goniotomy with a mean of  $1.1 \pm 0.1$   
130 procedures. Three eyes with PCG due to corneal edema and four eyes with secondary  
131 childhood glaucoma (2, AR anomaly and 2 aniridia) did not have goniotomies. Forty-one  
132 percent of infants with PCG had goniotomy repeated when the first goniotomy had reduced  
133 the IOP but to an unsatisfactory level. None of the secondary glaucoma cases had angle  
134 surgery repeated. The mean preoperative IOP was  $24.2 \pm 0.7$  mmHg using an average of  
135  $2.1 \pm 0.2$  glaucoma medications, with no children receiving pre-operative acetazolamide.  
136 The population was predominantly white but 23% were of black descent.

137



138 **Surgical Procedure and Follow-up Period**

139 There was a standard surgical approach in all cases as detailed above, with intraoperative  
140 MMC administered at a mean concentration of  $0.22 \pm 0.02$  mg/ml (range, 0.1 – 0.5mg/ml).  
141 Eighty-three percent of cases had either 0.1-0.2 mg/ml concentration of MMC during  
142 surgery. Higher doses of MMC, ie. 0.5mg/ml, were used in children of Black or Middle  
143 Eastern descent only. The mean duration of follow up in successful cases was  $72.9 \pm 5.7$   
144 months (range, 26-129 months) and failure was observed at a mean of  $29.0 \pm 8.2$  months  
145 (range, 1-90) .

146

147 **Surgical outcomes**

148 A summary of the postoperative care and outcomes at the final follow up for groups  
149 designated as success or failure is shown in Table 2.

150

151 Twenty-six of forty eyes (65.0%) were considered successful at the time of last follow up, of  
152 which 62.5% (25/40 cases) were regarded as a complete success and 2.5% (1/40 cases) a  
153 qualified success with the use of topical medication. The mean postoperative IOP at the last  
154 follow up visit for all successful eyes was  $11.9 \pm 0.7$  mmHg with a mean reduction of  $48.8\% \pm 4.0\%$   
155 from the preoperative baseline. Eyes classed as failures had a mean IOP of  $23.4 \pm 1.2$   
156 mmHg at the time of failure and achieved a mean final IOP of  $14.5 \pm 1.0$  mmHg with a  
157  $38.4\% \pm 5.1\%$  reduction from baseline after additional surgery. In addition to the IOP  
158 reading, glaucoma progression was determined by clinical signs and biometric parameters.  
159 Nine out of the fourteen failures had releasable sutures removed within the first 6 weeks and  
160 in seven this was also associated with needling. There was no significant difference  
161 between the dose of MMC, duration of postoperative topical steroids, the number of EUAs,  
162 5-fluorouracil (5-FU) or steroid injections administered to those deemed successful and  
163 those considered failures.

164

165 Kaplan-Meier life-table analysis (Figure 1) demonstrated a mean cumulative probability of  
166 success (95% confidence interval) at 6 months and 12 months (1 year) of 0.80 (0.64-0.89)  
167 and 0.78 (0.61-0.88) respectively. The cumulative probabilities of success at 60 months (5  
168 years) (modelled on 18 eyes) and at 87 months (7.3 years) (modelled on 9 eyes) after  
169 surgery were 0.67 (0.49-0.80) and 0.60 (0.38-0.76) respectively. When analyzed according  
170 to age at surgery, there was a trend towards greater success rates at the end of follow up  
171 observed in those twelve months or younger (70.4%) compared to of those over twelve  
172 months of age (53.8%). There was no difference in underlying diagnosis between the two  
173 groups. Life-table analysis comparing outcomes of cases of primary congenital glaucoma to  
174 those with secondary childhood glaucoma showed no significant difference in survival  
175 between these etiologies over the course of follow up (Figure 2).

176

177 Data from all eyes (including 14 children with both eyes included in the study) were used for  
178 analysis. There is potential for introducing bias by analyzing fellow eyes as independent  
179 entities. In order to address this, we performed Cox Regression allowing for clustering,  
180 which produced similar results to those found ignoring non independence. Of the 14 children  
181 who had two eyes included in the study, failure was observed in both eyes in 2 children,  
182 success was observed in both eyes in 5 children. The remaining children failed in one eye  
183 but were successful in their fellow eye. A test for symmetry was conducted ( $p=0.7$ ) indicating  
184 little evidence of an association (albeit with low power). These observations would suggest  
185 that our findings are robust to non-independence and justify the inclusion of data from all  
186 eyes in the analyses presented.

187

188 Final visual acuity in all eyes studied was  $0.69 \pm 0.1$  with 34.2% achieving the equivalent of  
189 20/40 or better, 89.5% seeing 20/200 or better and with no cases of loss of light perception.  
190 Almost half the children with successful outcomes had visual of acuity of 20/40 or better.

191

## 192 **Surgical Complications and Postoperative Interventions**

193 There were no recorded cases of hyphema, flat AC, early or late bleb leak, chronic  
194 hypotony, endophthalmitis or retinal detachment observed in this series. Choroidal effusions  
195 in the presence of a shallow AC and low IOP were observed in four cases (10%) with B-scan  
196 ultrasound routinely performed at one week after surgery. Only one of the cases was with  
197 the use of MMC 0.5mg/ml. Two cases resolved following intracameral viscoelastic injection,  
198 one case did not resolve following intracameral viscoelastic injection and underwent re-  
199 suturing of the scleral flap and the fourth resolved with conservative management. All four  
200 cases went on to have a successful outcome.

201

202 Only one of the 40 eyes developed a cystic avascular bleb with all the other eyes being non-  
203 cystic in nature (diffuse and elevated or flat). This specific case also suffered blebitis ten  
204 years after trabeculectomy although it responded well to topical and systemic antibiotic  
205 treatment alone with no change in IOP control or visual acuity. Diffuse, elevated bleb  
206 morphology was noted in 63% of eyes (25 eyes) and 35% (14 eyes) had a flat appearance,  
207 of which 86% (12 eyes) were observed in eyes classes as failures.

208

209 The presence of cataract, usually a small posterior subcapsular cataract, was noted in 20%  
210 (8/40) of all eyes across the study group. The presence of cataract was observed in 11.5%  
211 (3/26) eyes) in the group deemed to be successful at the end of follow up at a mean of  $33.7$   
212  $\pm 14.4$  months after trabeculectomy surgery. None of these patients required cataract  
213 surgery as their vision was not thought to have been significantly impacted by the cataract to  
214 warrant surgery (one case had visual acuity of 0.1 and the other 2 cases were unchanged at  
215 0.8 and 0.9). The majority of observed cataract formation (5/8 cases), including a single  
216 case that required surgery, occurred in the failure group at a mean of  $56.4 \pm 10.5$  months  
217 after trabeculectomy surgery. In these cases, cataract development occurred after further  
218 glaucoma surgeries in all cases (3 cases of needling followed by Baerveldt tube insertion, 1

219 case of needling followed by repeat trabeculectomy with MMC 0.5mg/ml adjacent to the  
220 original, 1 case of needling followed by cyclodiode laser).

221

## 222 **Reasons for Failure**

223 Postoperative interventions across the study group are summarized in Table 3. The fourteen  
224 eyes that failed all did so because of uncontrolled IOP requiring further intervention. All eyes  
225 that were considered as failures, were due to bleb needling being performed. These were  
226 performed at a mean  $28.2 \pm 7.5$  months after trabeculectomy with an average of two  
227 needlings performed per eye. Needling alone controlled the IOP in only 21.4% (3/14 eyes) of  
228 cases. Ultimately, after failed needlings (11/14 eyes), eight eyes underwent Baerveldt  
229 implant insertion, one eye underwent a repeat trabeculectomy with MMC 0.5 mg/ml, one eye  
230 required cyclodiode laser treatment and one eye underwent cyclodiode laser followed by  
231 Baerveldt implant insertion. There was a significant association with bleb needling and  
232 further glaucoma surgery being performed ( $p < 0.0001$ ). However despite this group being  
233 regarded as failures, they did achieve a mean final IOP of  $14.5 \pm 1.0$  mmHg with a mean 38.4  
234  $\pm 5.1\%$  reduction of IOP from baseline with no loss of light perception vision, indicating that  
235 needling procedures and subsequent surgeries were largely successful in the restoration of  
236 intraocular pressure control.

237

## 238 **Discussion**

239 Trabeculectomy has traditionally been the procedure of choice after failed angle surgery to  
240 control IOP in children. But in contrast to adults, trabeculectomy surgery in children is  
241 associated with poorer outcomes<sup>12, 13</sup> due to a more aggressive healing response<sup>14</sup> and the  
242 potential challenges of reduced compliance and lack of co-operation with examination.  
243 Nonetheless, success of MMC trabeculectomy in children has been reported to be 59-95%  
244 (IOP  $\leq 21$ mmHg) with short follow up of 2 years or less<sup>15-18, 20, 28</sup> reducing to 55% after 6  
245 years mean follow up<sup>29</sup>. All these studies are retrospective which makes comparison difficult

246 as success is influenced potentially by a number of factors such as: definition of success,  
247 patient's age and race, case mix (primary and secondary glaucomas), inclusion of non  
248 phakic patients, previous surgery, surgical technique, dose and duration of MMC, use of 5-  
249 FU post operatively and duration of follow up.

250

251 In a number of studies, infancy has been shown to be a significant risk factor for failure.  
252 Reported outcomes of trabeculectomy in infants less than one year of age vary between 15-  
253 43%<sup>15, 16, 18, 20</sup>. Beck *et al*<sup>20</sup> reported that being aged less than 1 year at the time of surgery  
254 was associated with almost a six-fold risk of failure. For infants less than 2 years of age,  
255 Beck *et al*<sup>21</sup> reported a cumulative success rate of 36% (IOP < 23mmHg with medications) in  
256 24 eyes at 1 year which dropped to only 19% at 6 years in a group with both primary and  
257 secondary childhood glaucoma which included aphakic and pseudophakic patients. In a  
258 larger series, Al Hazmi *et al* described a success rate of 39% (IOP < 21mmHg without  
259 topical medications) in 66 eyes (unreported follow up) in a study population mostly of PCG  
260 patients from the Middle East<sup>15</sup>.

261

262 In comparison, our long-term outcomes of trabeculectomy with MMC for glaucoma  
263 presenting in infants less than 2 years of age are more encouraging, with a cumulative  
264 probability of success at one and seven years of 78% and 60% respectively. Almost all  
265 successful cases (25/26; 96%) were not using topical IOP lowering medications at final  
266 follow up. In infants less than one year of age, 70% were successful at the end of follow up.

267

268 The significant difference in outcomes of our study compared to published reports may  
269 relate to a number of factors. Our study group was predominantly white, PCG cases and  
270 included no patients with aphakia /pseudophakia or previous surgery involving the  
271 conjunctiva, both known to be significant risk factors for trabeculectomy failure<sup>13, 20, 30-33</sup>.

272 The pre-operative IOP in our series was lower than in comparable series which may have  
273 contributed to improved outcomes. Furthermore surgical technique, namely MMC treatment

274 under the scleral flap also performed by other authors<sup>15, 18</sup> and close post-operative  
275 management with further subconjunctival 5-FU and steroid may have also played a role. It is  
276 likely the intensive post-operative bleb management achieved early diffuse posterior  
277 aqueous flow, which contributed to successful long-term outcomes. Although it could be  
278 argued that a significant number of EUAs were necessary, this has to be seen within the  
279 context of overall results and that in successful cases (65%) one operation was all that was  
280 necessary to achieve glaucoma stability over the duration of follow up. In comparison, Taylor  
281 and colleagues<sup>1</sup> describe children with PCG (117 patients) requiring on average of  $4.3 \pm 3.8$   
282 (range 0-23) operations over a 20 year observation period to manage their glaucoma.

283

284 Trabeculectomy surgery in young children has fallen out of favor not only because of  
285 reported poor outcomes but also because of the association with significant surgical  
286 complications including flat anterior chambers (10%), choroidal effusions (22%),  
287 suprachoroidal hemorrhage, retinal detachments and phthisis<sup>18, 20</sup>. In particular, thin  
288 avascular, cystic blebs commonly occurred,<sup>16,18</sup> predisposing to bleb related infection such  
289 as endophthalmitis (5-8%)<sup>20, 29</sup>, and chronic late, bleb leaks (23%)<sup>16</sup>. As a consequence,  
290 contemporary pediatric trabeculectomy techniques have evolved in recent years from those  
291 used by comparative papers (e.g. limbus-based conjunctival flap and fixed sutures) with the  
292 aim of reducing the burden of complications.<sup>24, 25,27</sup> All cases in this series were performed  
293 using a standardized technique based on the Moorfields Safer Surgery System<sup>24, 25</sup> aimed at  
294 achieving posteriorly directed aqueous flow. Specific modifications for pediatric  
295 trabeculectomies include limited radial cuts to avoid anterior limbal flow and excessive flow  
296 through the flap, MMC treatment under the scleral flap as well as the subconjunctival tissue  
297 and the use of an AC maintainer in all cases.

298

299 In our study the commonest early complication was choroidal effusion at one week after  
300 surgery in 10% (4/40 eyes), which is lower than the published literature which ranges from

301 17-23%.<sup>16, 20, 21</sup> Susanna *et al.*<sup>18</sup> reported a 5% rate of choroidal detachment but suspected it  
302 was higher some eyes with shallow anterior chambers were not fully dilated when examined.  
303 Our observed rate of cataract development in the cohort with successful outcome (11.5% -  
304 none requiring surgery) was comparable to the existing literature for the same duration of  
305 follow up<sup>21</sup>.

306

307 The accepted alternative to trabeculectomy following failed angle surgery is the insertion of a  
308 glaucoma drainage device (GDD). Only a few studies specifically evaluate the performance  
309 of GDD in the infant population. Success rates at one year are reported at 74-87%<sup>21, 34</sup> with  
310 53% survival at 6 years after surgery<sup>21</sup>. Our trabeculectomy outcomes are comparable  
311 although direct comparison is difficult due to the presence of aphakic glaucoma cases in  
312 these populations. However the major difference between our findings and those reported  
313 following tube surgery is the significant associated complications often requiring surgical  
314 revision. Beck *et al* reported 45.7% of eyes with a GDD required one or more operations due  
315 to a complication related to the implant (most commonly tube corneal touch and exposure),  
316 in contrast to 12.5% of eyes in trabeculectomy group<sup>21</sup>. Tube malposition, erosion and  
317 endophthalmitis are consistently reported with greater frequency in the pediatric compared  
318 to adult population<sup>3</sup>. Tube malposition requiring further surgery has been reported in 26-  
319 35% of cases<sup>21, 34</sup>. These studies also reported corneal decompensation (9%), vitreous  
320 hemorrhage (7%), endophthalmitis (7%) and retinal detachment (7%) following GDD  
321 surgery. Overall, complications in our series were fewer than reported in comparable  
322 literature following trabeculectomy and glaucoma drainage device surgery. This is important  
323 as the technique is simple and does not require expensive special equipment. Furthermore  
324 of significance, the need for medications appears to be higher following GDD compared to  
325 trabeculectomy.<sup>20</sup> In one study, only 14% of infants undergoing GDD surgery achieved IOP  
326 control without topical medications<sup>34</sup> compared to 62.5% (25/40) of our trabeculectomy  
327 cases.

328

329 Criteria for success in glaucoma are largely based on IOP related parameters and the  
330 absence of serious complications. However, the preservation of visual function is the goal in  
331 these children and is influenced by factors other than IOP, such as corneal clarity, refractive  
332 status and amblyopia which must also be addressed. In our study, final overall visual acuity  
333 outcomes of 34.2% seeing 20/40 or better, 89.5% seeing 20/200 or better and no cases of  
334 loss of light perception were very encouraging and comparable to other published reports.<sup>35</sup>

335

336 This study is limited by the retrospective nature of the analysis and with the study population  
337 comprising predominantly cases of primary congenital glaucoma. A randomized, multicentre  
338 trial comparing MMC trabeculectomy and GDD would be of interest, as would a study on the  
339 optimal MMC application method, concentration and duration.

340

341 In conclusion, this study demonstrates that MMC augmented trabeculectomy using simple  
342 contemporary trabeculectomy techniques is an effective option in the management of  
343 glaucoma within the first two years of life, as shown by the successful long-term outcomes  
344 and low incidence of sight threatening complications. After failed goniotomy surgery or as  
345 primary surgery for phakic secondary childhood glaucoma cases, trabeculectomy may offer  
346 an infant with glaucoma an excellent opportunity to achieve long-term control of intraocular  
347 pressure off medications and optimal visual outcomes. The close post-operative monitoring  
348 and need for regular EUA required to achieve these results in comparison to GDD surgery is  
349 balanced by the significantly lower surgical re-intervention rate and dependence on  
350 medication for IOP control. Should failure occur later in life, the opportunity for GDD still  
351 exists and the potential complications of such surgery will be delayed, perhaps beyond the  
352 more critical period of visual maturation.

353

## 354 **References**

355



- 356 1. Taylor RH, Ainsworth JR, Evans AR, Levin AV. The epidemiology of pediatric  
357 glaucoma: the Toronto experience. *J aapos* 1999;3(5):308-15.
- 358 2. Aponte EP, Diehl N, Mohny BG. Medical and surgical outcomes in childhood  
359 glaucoma: a population-based study. *J aapos* 2011;15(3):263-7.
- 360 3. Chen TC, Chen PP, Francis BA, et al. Pediatric glaucoma surgery: a report by the  
361 american academy of ophthalmology. *Ophthalmology* 2014;121(11):2107-15.
- 362 4. Papadopoulos M, Cable N, Rahi J, Khaw PT. The British Infantile and Childhood  
363 Glaucoma (BIG) Eye Study. *Invest Ophthalmol Vis Sci* 2007;48(9):4100-6.
- 364 5. Zhang XL, Du SL, Ge J, et al. [Quality of life in patients with primary congenital  
365 glaucoma following antiglaucoma surgical management]. *Zhonghua Yan Ke Za Zhi*  
366 2009;45(6):514-21.
- 367 6. Papadopoulos M, Edmunds B, Chiang M, et al. Glaucoma Surgery in Children. In:  
368 Weinreb RN, Grajewski AL, Papadopoulos M, et al., eds. *WGA Consensus Series 9-  
369 Childhood Glaucoma* Amsterdam: Kugler Publications, 2013.
- 370 7. Anderson DR. Trabeculotomy compared to goniotomy for glaucoma in children.  
371 *Ophthalmology* 1983;90(7):805-6.
- 372 8. McPherson SD, Jr., McFarland D. External trabeculotomy for developmental  
373 glaucoma. *Ophthalmology* 1980;87(4):302-5.
- 374 9. Russell-Eggitt IM, Rice NS, Jay B, Wyse RK. Relapse following goniotomy for  
375 congenital glaucoma due to trabecular dysgenesis. *Eye (Lond)* 1992;6 ( Pt 2):197-200.
- 376 10. Luntz MH. Congenital, infantile, and juvenile glaucoma. *Ophthalmology*  
377 1979;86(5):793-802.
- 378 11. Rice NSC. The Surgical Management of the Congenital Glaucomas. *Australian  
379 Journal of Ophthalmology* 1977;5(3):174-9.
- 380 12. Gressel MG, Heuer DK, Parrish RK, 2nd. Trabeculectomy in young patients.  
381 *Ophthalmology* 1984;91(10):1242-6.
- 382 13. Inaba Z. Long-term results of trabeculectomy in the Japanese: an analysis by life-  
383 table method. *Jpn J Ophthalmol* 1982;26(4):361-73.
- 384 14. Beauchamp GR, Parks MM. Filtering surgery in children: barriers to success.  
385 *Ophthalmology* 1979;86(1):170-80.
- 386 15. al-Hazmi A, Zwaan J, Awad A, et al. Effectiveness and complications of mitomycin C  
387 use during pediatric glaucoma surgery. *Ophthalmology* 1998;105(10):1915-20.
- 388 16. Freedman SF, McCormick K, Cox TA. Mitomycin C-augmented trabeculectomy with  
389 postoperative wound modulation in pediatric glaucoma. *J AAPOS* 1999;3(2):117-24.
- 390 17. Sidoti PA, Belmonte SJ, Liebmann JM, Ritch R. Trabeculectomy with mitomycin-C in  
391 the treatment of pediatric glaucomas. *Ophthalmology* 2000;107(3):422-9.

- 392 18. Susanna R, Jr., Oltrogge EW, Carani JC, Nicolela MT. Mitomycin as adjunct  
393 chemotherapy with trabeculectomy in congenital and developmental glaucomas. *J*  
394 *Glaucoma* 1995;4(3):98151-7.
- 395 19. Waheed S, Ritterband DC, Greenfield DS, et al. Bleb-related ocular infection in  
396 children after trabeculectomy with mitomycin C. *Ophthalmology* 1997;104(12):2117-20.
- 397 20. Beck AD, Wilson WR, Lynch MG, et al. Trabeculectomy with adjunctive mitomycin C  
398 in pediatric glaucoma. *Am J Ophthalmol* 1998;126(5):648-57.
- 399 21. Beck AD, Freedman S, Kammer J, Jin J. Aqueous shunt devices compared with  
400 trabeculectomy with Mitomycin-C for children in the first two years of life. *Am J Ophthalmol*  
401 2003;136(6):994-1000.
- 402 22. Englert JA, Freedman SF, Cox TA. The Ahmed valve in refractory pediatric  
403 glaucoma. *Am J Ophthalmol* 1999;127(1):34-42.
- 404 23. Fellenbaum PS, Sidoti PA, Heuer DK, et al. Experience with the baerveldt implant in  
405 young patients with complicated glaucomas. *J Glaucoma* 1995;4(2):91-7.
- 406 24. Khaw PT, Chiang M, Shah P, et al. Enhanced trabeculectomy: the Moorfields Safer  
407 Surgery System. *Dev Ophthalmol* 2012;50:1-28.
- 408 25. Khaw PT, Wilkins MR, Shah P. Glaucoma Surgery. In: Easty D, Sparrow J, eds.  
409 *Oxford Textbook of Ophthalmology*: Oxford University Press, 1999.
- 410 26. Solus JF, Jampel HD, Tracey PA, et al. Comparison of limbus-based and fornix-  
411 based trabeculectomy: success, bleb-related complications, and bleb morphology.  
412 *Ophthalmology* 2012;119(4):703-11.
- 413 27. Wells AP, Cordeiro MF, Bunce C, Khaw PT. Cystic bleb formation and related  
414 complications in limbus- versus fornix-based conjunctival flaps in pediatric and young adult  
415 trabeculectomy with mitomycin C. *Ophthalmology* 2003;110(11):2192-7.
- 416 28. Mandal AK, Walton DS, John T, Jayagandan A. Mitomycin C-augmented  
417 trabeculectomy in refractory congenital glaucoma. *Ophthalmology* 1997;104(6):996-1001;  
418 discussion 2-3.
- 419 29. Giampani J, Jr., Borges-Giampani AS, Carani JC, et al. Efficacy and safety of  
420 trabeculectomy with mitomycin C for childhood glaucoma: a study of results with long-term  
421 follow-up. *Clinics (Sao Paulo)* 2008;63(4):421-6.
- 422 30. Azuara-Blanco A, Wilson RP, Spaeth GL, et al. Filtration procedures supplemented  
423 with mitomycin C in the management of childhood glaucoma. *Br J Ophthalmol*  
424 1999;83(2):151-6.
- 425 31. Mandal AK, Bagga H, Nutheti R, et al. Trabeculectomy with or without mitomycin-C  
426 for paediatric glaucoma in aphakia and pseudophakia following congenital cataract surgery.  
427 *Eye (Lond)* 2003;17(1):53-62.

- 428 32. Broadway DC, Grierson I, Hitchings RA. Local effects of previous conjunctival  
429 incisional surgery and the subsequent outcome of filtration surgery. *Am J Ophthalmol*  
430 1998;125(6):805-18.
- 431 33. Dietlein TS, Jacobi PC, Krieglstein GK. Prognosis of primary ab externo surgery for  
432 primary congenital glaucoma. *Br J Ophthalmol* 1999;83(3):317-22.
- 433 34. Almobarak F, Khan AO. Complications and 2-year valve survival following Ahmed  
434 valve implantation during the first 2 years of life. *Br J Ophthalmol* 2009;93(6):795-8.
- 435 35. Biglan AW. Glaucoma in children: are we making progress? *J AAPOS* 2006;10(1):7-  
436 21.

437

438

439 **Tables and Figures**

440 

---

 Table 1. Baseline Demographic Information 

---

|     |  |                                      |
|-----|--|--------------------------------------|
| 441 |  |                                      |
| 442 | Patients   | 26                                   |
| 443 | Eyes   | 40                                   |
| 444 | Age (range (mean $\pm$ SE))                            | 1 – 19 months (9.0 $\pm$ 0.8 months) |
| 445 | Number of previous goniotomies (mean, SE)              | 1.1 $\pm$ 0.1                        |
| 446 | Diagnosis (n, %)                                       |                                      |
| 447 | Primary Congenital Glaucoma                            | 32 (80%)                             |
| 448 | Axenfeld-Rieger Anomaly                                | 4 (10%)                              |
| 449 | Aniridia   | 2 (5%)                               |
| 450 | Naevus of Ota  | 1 (2.5%)                             |
| 451 | Cutis Marmorata Telangiectasia                         | 1 (2.5%)                             |
| 452 | Ethnicity/Race (n, %)                                  |                                      |
| 453 | White  | 26 (65%)                             |
| 454 | Black  | 9 (22.5%)                            |
| 455 | Asian  | 3 (7.5%)                             |
|     | Middle Eastern   | 1 (2.5%)                             |
|     | Mixed  | 1 (2.5%)                             |
|     | Number of topical pre-operative medications (mean, SE) | 2.1 $\pm$ 0.2                        |
|     | Pre-operative IOP (mean, SE)                           | 24.2mmHg $\pm$ 0.7                   |

SE= standard error  
IOP= intraocular pressure

Table 2. Summary of Final Follow up

|   | <i>Total</i>                | <i>Success</i>               | <i>Failure</i>                                 |
|---|-----------------------------|------------------------------|--|
| Eyes  | 40                          | 26 (65%)                     | 14 (35%)                                       |
| Time to final follow up (months)                    | 62.8 ± 5.7<br>(Range 1-129) | 72.9 ± 5.7<br>(Range 26-129) | 29.0 ± 8.2 († <sup>***</sup> )<br>(Range 1-90) |
| Mean concentration of MMC (mg/ml)                   | 0.22 (range 0.1-0.5)        | 0.22 (range 0.1-0.5)         | 0.23 (range 0.1-0.5)                           |
| Number of EUAs                                      | 3.6 ± 0.2                   | 3.5 ± 0.2                    | 3.9 ± 0.3                                      |
| Number of Needlings                                 | 0.7 ± 0.2                   | 0                            | 1.9 ± 0.2(† <sup>**</sup> )                    |
| Releasable Sutures Removed/Adjusted                 | 11/40 (27.5%)               | 2/26 (7.7%)                  | 9/14 (64.3%)                                   |
| Number of Steroid Injections                        | 2.0 ± 0.2                   | 1.8 ± 0.2                    | 2.5 ± 0.4                                      |
| Number of 5-FU injections                           | 2.1 ± 0.2                   | 1.8 ± 0.2                    | 2.6 ± 0.4                                      |
| Duration of postoperative topical steroids (months) | 3.2 ± 0.3                   | 3.1 ± 0.3                    | 3.4 ± 0.5                                      |
| IOP at Failure (mmHg)                               |                             |                              | 23.4 ± 1.2                                     |
| Final IOP (mmHg)                                    | 12.8 ± 0.6                  | 11.9 ± 0.7                   | 14.5 ± 1.0 (‡ <sup>*</sup> )                   |
| Mean % IOP Reduction from Baseline                  | 45.2% ± 3.2                 | 48.8% ± 4.0                  | 38.4% ± 5.1(† <sup>*</sup> )                   |
| Final VA (logMAR)                                   | 0.69 ± 0.1                  | 0.41 ± 0.1                   | 1.2 ± 0.3 († <sup>**</sup> )                   |
| 20/40 or better                                     | 34.2% (13/38)               | 44.0% (11/25)                | 15.4% (2/13)                                   |
| 20/200 or better                                    | 89.5% (34/38)               | 92.0% (23/25)                | 69.2% (9/13)                                   |

456  
457 Data shown as mean ± standard error  
458

459 **Table 2.** Summary of data at final follow up denoting observations of the total sample (40  
460 eyes), eyes classified as having successful outcomes and eyes classified as failure. The  
461 populations of successful eyes and those classified a failure were tested for normality using  
462 the D’Agostino & Pearson normality test and compared with a two-tailed unpaired t-test with  
463 Welch’s correction (‡) if normality was shown else with a Mann-Whitney test (†). Observed  
464 significant differences are indicated in the table (<sup>\*\*\*</sup>  $p < 0.0004$ ; <sup>\*\*</sup>  $p < 0.0032$ ; <sup>\*</sup>  $p < 0.04$ ).  
465 (EUA = Examination under anesthesia; 5-FU = 5-Fluorouracil; MMC = Mitomycin-C; VA =  
466 visual acuity; IOP = intraocular pressure)

467

Table 3. Post-operative Surgical Interventions

468

|                       |             |
|-----------------------|-------------|
| Scleral flap resuture | 1/40 (2.5%) |
|-----------------------|-------------|

469

|               |               |
|---------------|---------------|
| Bleb needling | 12/40 (30.0%) |
|---------------|---------------|

470

|                       |             |
|-----------------------|-------------|
| Repeat Trabeculectomy | 1/40 (2.5%) |
|-----------------------|-------------|

|                  |             |
|------------------|-------------|
| Cyclodiode Laser | 2/40 (5.0%) |
|------------------|-------------|

471

|                         |              |
|-------------------------|--------------|
| Aqueous Shunt Insertion | 9/40 (22.5%) |
|-------------------------|--------------|

472

473

**Table 3.** Summary of postoperative procedures performed across all eyes during the follow

474

up period. A single case of early hypotony unresponsive to an anterior chamber injection of


475

viscoelastic required scleral flap re-suture and went on to be a success.

476

477

478




479

480

481 **Figure 1.** Cumulative surgical success after Mitomycin augmented trabeculectomy in infants  
 482 by Kaplan-Meier life-table analysis. Plotted is the probability of success vs follow-up time  
 483 (error bars represent the 95% confidence interval). Mean cumulative probabilities of success  
 484 (95% confidence interval) at 6 months and 12 months (1 year) were 0.80 (0.64-0.89) and  
 485 0.78 (0.61– 0.88) respectively. The cumulative probabilities of success at 60 months (5  
 486 years) and at 87 months (7.3 years) after surgery were 0.67 (0.49–0.80) and 0.60 (0.38–  
 487 0.76) respectively.

488



489

490

491 **Figure 2.** Cumulative surgical success by etiology after Mitomycin augmented  
492 trabeculectomy in infants by Kaplan-Meier life-table analysis. Plotted is the probability of  
493 success vs follow-up time for primary congenital glaucoma (solid line) and secondary  
494 glaucomas (dotted line). The two curves were not significantly different when compared  
495 using the log-rank (Mantel-Cox) test.

496

497